Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for perioperative anxiety and depression in thoracoscopic pulmonary nodule resection
ChiCTR2200055232Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in anxiety disorder, major depressive disorder (MDD) and postoperative pain (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Self-rating Anxiety Scale (SAS) score, Self-rating Depression Scale (SDS) score and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2200055232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055232.